Saliogen Therapeutics Overview

  • Founded
  • 2020
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $115M
Latest Deal Amount
  • Investors
  • 9

Saliogen Therapeutics General Information

Description

Developer of genome engineering platform designed to provide durable, safe, and affordable non-viral gene therapy to patients with inherited diseases. The company's genome engineering technology is mammal-derived, to be used in potentially curative non-viral gene therapy, enabling the healthcare industry to treat patients in need.

Contact Information

Website
www.saliogen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 245 First Street
  • 18th Floor
  • Cambridge, MA 02142
  • United States
+1 (857) 000-0000

Saliogen Therapeutics Timeline

20212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Saliogen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 05-Jan-2022 $115M 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 07-Dec-2021 000.00 000.00 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 18-Feb-2021 $20M $20M 0000 Completed Generating Revenue
To view Saliogen Therapeutics’s complete valuation and funding history, request access »

Saliogen Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 0,000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 0,000,000 00.000000 000.0 000.0 00 000.0 00.000
To view Saliogen Therapeutics’s complete cap table history, request access »

Saliogen Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Raymond Tabibiazar MD Chief Executive Officer & Chairman
Sung You Chief Business and Strategy Officer
Joseph Higgins MD Founder, Chief Scientific Officer, President & Board Member
Susan Romagnoli Controller
Mark McClellan Ph.D Executive Advisor
You’re viewing 5 of 6 executive team members. Get the full list »

Saliogen Therapeutics Board Members (5)

Name Representing Role Since
Craig Gordon MD Self Board Member 000 0000
Joseph Higgins MD Saliogen Therapeutics Founder, Chief Scientific Officer, President & Board Member 000 0000
Raymond Tabibiazar MD Saliogen Therapeutics Chief Executive Officer & Chairman 000 0000
Sean Stalfort PBM Capital Group Board Member 000 0000
Sukumar Nagendran MD Self Board Member 000 0000
To view Saliogen Therapeutics’s complete board members history, request access »

Saliogen Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Saliogen Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cystic Fibrosis Foundation Corporation Minority 000 0000 000000 0
D1 Capital Partners Hedge Fund Minority 000 0000 000000 0
Fidelity Management & Research PE/Buyout Minority 000 0000 000000 0
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority 000 0000 000000 0
SymBiosis Capital Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial